ArticleThe ocular surface2023
Meibomian gland stem/progenitor cells: The hunt for gland renewal.
Article in The ocular surface, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Effect of Meibomian Gland Expression on Meibomian Gland Regeneration and Function: A Randomized Controlled Trial.Clinical ophthalmology (Auckland, N.Z.) · 2026Trial
- Ferroptosis in Meibomian Gland Progenitor Cells Contributes to Pathogenesis of Meibomian Gland Dysfunction.Investigative ophthalmology & visual science · 2026Article
- DHCR24 Deficiency Drives Age-Related Meibomian Gland Dysfunction by Regulating Lipid Metabolic Imbalance and Cytosolic mtDNA-Induced cGAS-STING Activation.International journal of biological sciences · 2026Article
- Ocular social jetlag: a driver of immune-metabolic dysfunction in dry eye disease.Frontiers in immunology · 2026Review
- Spatial transcriptome analysis of the human eyelid depicts meibomian gland cell differentiation: A pilot study.Physiological reports · 2025Article
- Identification of Meibomian gland stem cell populations and mechanisms of aging.Nature communications · 2025Article
- Atrophic meibomian gland dysfunction induced by eyelid margin cryotherapy with liquid nitrogen.Scientific reports · 2025Article
- Deletion of Fgfr2 in Ductal Basal Epithelium With Tamoxifen Induces Obstructive Meibomian Gland Dysfunction.Investigative ophthalmology & visual science · 2024Article
- Identification of Meibomian gland stem cell populations and mechanisms of aging.bioRxiv : the preprint server for biology · 2024Article
- The Yin and Yang of non-immune and immune responses in meibomian gland dysfunction.The ocular surface · 2024Article
- Expression of ATP-Binding Cassette Transporter A1 (ABCA1) in Eyelid Tissues and Meibomian Gland Epithelial Cells.Investigative ophthalmology & visual science · 2024Article
- Standardization of meibomian gland dysfunction in an Egyptian population sample using a non-contact meibography technique.International journal of ophthalmology · 2024Article
- Meibomian Gland Probing Stimulates a Proliferative Epithelial Response Resulting in Duct Regeneration.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Recent advances in age-related meibomian gland dysfunction (ARMGD).The ocular surface · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Meibomian glands (MGs) secrete lipid (meibum) onto the ocular surface to form the outermost layer of the tear film. Proper meibum secretion is essential for stabilizing the tear film, reducing aqueous tear evaporation, and maintaining the homeostasis of the ocular surface. Atrophy of MG as occurs with aging, leads to reduction of meibum secretion, loss of ocular surface homeostasis and evaporative dry eye disease (EDED). Since MGs are holocrine glands, secretion of meibum requires continuous self-renewal of lipid-secreting acinar meibocytes by stem/progenitor cells, whose proliferative potential is dramatically reduced with age leading to MG atrophy and an age-related meibomian gland dysfunction (ARMGD). Understanding the cellular and molecular mechanisms regulating meibocyte stem/progenitor cell maintenance and renewal may provide novel approaches to regenerating MG and treating EDED. Towards that end, recent label retaining cell and lineage-tracing experiments as well as knock-out transgenic mouse studies have begun to identify the location and identities of meibocyte progenitor cells and potential growth and transcription factors that may regulate meibocyte renewal. In addition, recent reports have shown that ARMGD may be reversed by novel therapeutics in mice. Herein, we discuss our current understanding of meibocyte stem/progenitor cells and the hunt for gland renewal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.